MCRB
Seres Therapeutics, Inc.Company Information
- Company Name
- Seres Therapeutics, Inc.
- CIK
- CIK0001609809
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- MCRB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MCRB
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-08-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 4,482
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,305,453
- Shares outstanding
- 9,706,193
- Ownership
- 23.75%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 2.10%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 16 | 30 | 46 | 48 | 45 | 59 | 31 | 67 | 71 | 111 | 128 | 170 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Inventory Net | - | - | - | - | - | - | - | - | 53 | 42 | 30 | 19 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | 0 | 0 | - | - | 39 | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 2 | 3 | 3 | 2 | 4 | 6 | 6 | 6 | 5 | 8 | 9 | ||||||
| Assets Current | 42 | 32 | 49 | 52 | 49 | 66 | 39 | 73 | 149 | 165 | 175 | 214 | ||||||
| Property Plant And Equipment Net | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 18 | 19 | 18 | 24 | ||||||
| Operating Lease Right Of Use Asset | 51 | 70 | 72 | 75 | 77 | 79 | 81 | 83 | 103 | 106 | 90 | 108 | ||||||
| Restricted Cash Noncurrent | 2 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 8 | 8 | 8 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42 | 41 | 2 | 12 | ||||||
| Restricted Investments Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Assets | 102 | 118 | 138 | 143 | 144 | 164 | 140 | 179 | 322 | 341 | 359 | 368 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | - | - | 0 | 0 | - | - | 63 | - | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 8 | 5 | 5 | 4 | 9 | ||||||
| Operating Lease Liability Current | 12 | 11 | 10 | 10 | 9 | 9 | 9 | 8 | 9 | 9 | 6 | 6 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Deferred Income | - | - | - | - | - | - | - | - | 8 | 8 | 8 | 9 | ||||||
| Liabilities Current | 20 | 19 | 19 | 22 | 31 | 31 | 41 | 65 | 108 | 98 | 99 | 79 | ||||||
| Operating Lease Liability Noncurrent | 45 | 70 | 73 | 75 | 78 | 80 | 83 | 85 | 101 | 103 | 92 | 105 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | 0 | 0 | - | - | 67 | - | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities | 67 | 91 | 94 | 100 | 111 | 114 | 126 | 155 | 409 | 401 | 403 | 383 | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | 0 | 0 | 102 | 102 | 102 | 101 | ||||||
Stockholders Equity | ||||||||||||||||||
| Derivative Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | - | - | - | - | - | - | 0 | 0 | - | - | 109 | - | ||||||
| Additional Paid In Capital Common Stock | 1,022 | 1,019 | 1,017 | 1,001 | 998 | 996 | 992 | 986 | 964 | 958 | 933 | 922 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -988 | -992 | -972 | -957 | -965 | -945 | -978 | -962 | -1,051 | -1,018 | -978 | -937 | ||||||
| Stockholders Equity | 35 | 26 | 44 | 44 | 33 | 50 | 14 | 24 | -87 | -60 | -45 | -15 | ||||||
| Liabilities And Stockholders Equity | 102 | 118 | 138 | 143 | 144 | 164 | 140 | 179 | 322 | 341 | 359 | 368 | ||||||
| Related Party | - | - | - | - | - | - | - | - | - | - | - | 3 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 360 | 360 | 360 | 360 | 360 | 360 | 360 | 360 | 360 | 240 | 240 | 240 | ||||||
| Common Stock Shares Issued | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 7 | 6 | ||||||
| Shares Outstanding | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 7 | 6 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSeres Therapeutics, Inc. (MCRB) — SEC Financial Statements & Analysis
Seres Therapeutics, Inc. (MCRB) is a pharmaceutical preparations company, incorporated in DE. Seres Therapeutics, Inc. trades on Nasdaq as: MCRB. Seres Therapeutics, Inc. (MCRB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Seres Therapeutics, Inc. carries a market cap of $76.58M, a P/E ratio of 2.54x, a P/B ratio of 2.22x, a P/S ratio of 40.67x, an enterprise value of $58.74M, and an EV/EBITDA multiple of -0.68x. On profitability, it posts an operating margin of -4798.88%, a net margin of 1600.21%, a Return on Equity (ROE) of 89.30%, and a Return on Assets (ROA) of 24.56%. Per share, it reports EPS of $3.10, diluted EPS of $3.09, free cash flow per share of $-5.28, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 448.44% year-over-year, net income growth of 129.12% year-over-year, and EPS growth of 106.40% year-over-year. On the balance sheet, it maintains a current ratio of 2.11x, a quick ratio of 2.04x, working capital of $22.32M, a debt-to-equity ratio of 1.94x, a debt ratio of 0.66, an interest coverage ratio of -179.02x, free cash flow of $-51.30M (TTM), and net debt of $-17.84M. Figures sourced from SEC EDGAR.
- Market Cap
- $76.58M
- P/E TTM
- 2.54x
- EPS TTM
- $3.10
- P/B TTM
- 2.22x
- ROE TTM
- 89.30%
- ROA TTM
- 24.56%
- Debt To Equity
- 1.94x
- Free Cash Flow TTM
- $-51.30M
- Net Revenue TTM Growth 1Y
- 448.44%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Seres Therapeutics, Inc. in?
Seres Therapeutics, Inc. (MCRB) operates in the Pharmaceutical Preparations industry.
What exchange does MCRB trade on?
Seres Therapeutics, Inc. (MCRB) trades on the Nasdaq.
Where is Seres Therapeutics, Inc. incorporated?
Seres Therapeutics, Inc. is incorporated in DE.
When was Seres Therapeutics, Inc. (MCRB)'s most recent SEC filing?
Seres Therapeutics, Inc. (MCRB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is MCRB's market cap?
Seres Therapeutics, Inc. (MCRB) has a market capitalization of $76.58M as of 2026-06-30.
What is MCRB's P/E ratio?
Seres Therapeutics, Inc. (MCRB)'s trailing twelve month P/E ratio is 2.54x as of 2026-06-30.
What is MCRB's EPS (earnings per share)?
Seres Therapeutics, Inc. (MCRB)'s trailing twelve month EPS is $3.10 as of 2026-06-30.
What is MCRB's ROE (return on equity)?
Seres Therapeutics, Inc. (MCRB)'s trailing twelve month Return on Equity (ROE) is 89.30% as of 2026-06-30.
What is MCRB's ROA (return on assets)?
Seres Therapeutics, Inc. (MCRB)'s trailing twelve month Return on Assets (ROA) is 24.56% as of 2026-06-30.
What is MCRB's EV/EBITDA?
Seres Therapeutics, Inc. (MCRB)'s trailing twelve month EV/EBITDA is -0.68x as of 2026-06-30.